GLP-SM

GLP-SM

Trusted & appreciated by 5,000+ researchers

£50.00

COA
Buy Now
Stock up & save
£50.00
1 Vial
8% Off
£46.00
2 Vials
15% Off
£43.00
3 Vials
22% Off
£39.00
5 Vials
30% Off
£35.00
Kit (10 Vials)
Research Use Only: These products are intended for laboratory research purposes only. By purchasing, you confirm you are a qualified researcher and understand this product is not for personal use.
Visa
Mastercard
Google Pay
SEPA
iDEAL
Bitcoin
Ethereum
USDT
SKU: SM10 Category:

Description

Semaglutide

GLP-SM is a synthetic, long-acting analogue of glucagon-like peptide-1 (GLP-1) — a hormone naturally released by the gut after eating. It was originally developed to study blood sugar regulation and has since become one of the most extensively researched peptides in metabolic science (Carvalho et al., 2025).

Mechanism of Action

  • GLP-SM binds to and activates GLP-1 receptors found in the pancreas, brain, gut, and cardiovascular system, triggering insulin release in response to food while simultaneously reducing the release of glucagon — a hormone that raises blood sugar
  • It slows the rate at which the stomach empties, which prolongs feelings of fullness and reduces overall food intake
  • In the brain, GLP-1 receptor activation reduces appetite signals in areas responsible for hunger and reward, contributing to reduced caloric intake (Sikiric et al., 2025)
  • GLP-SM is engineered with a fatty acid side chain that binds to albumin in the bloodstream, extending its half-life to approximately one week and enabling once-weekly dosing (Maharjan & Panda, 2022)

Key Research Findings

  • The STEP clinical trial programme documented a mean body weight reduction of 14.9% with semaglutide 2.4 mg versus 2.4% with placebo in subjects without diabetes over 68 weeks (Carvalho et al., 2025)
  • The SELECT cardiovascular outcomes trial found GLP-SM reduced major adverse cardiovascular events by 20% compared to placebo in subjects with established cardiovascular disease and overweight, but without diabetes (Lincoff et al., 2023)
  • Research also demonstrates benefits in liver fat reduction, kidney function, and heart failure outcomes, pointing to a broad range of metabolic effects beyond blood sugar and weight (Trujillo et al., 2025)

For research use only. Not intended for use in humans or animals.

References

Carvalho, M., Figueiredo, R., & Costa, P. (2025). https://pubmed.ncbi.nlm.nih.gov/40143174/

Lincoff, A. M., Brown-Frandsen, K., Colhoun, H. M., Deanfield, J., Emerson, S. S., Esbjerg, S., & Nissen, S. E. (2023). https://www.nejm.org/doi/full/10.1056/NEJMoa2307563

Maharjan, R., & Panda, S. (2022). https://pmc.ncbi.nlm.nih.gov/articles/PMC8736331/

Sikiric, P., Drmic, D., Zucko, J., & Stupnisek, M. (2025). https://pmc.ncbi.nlm.nih.gov/articles/PMC11674233/

Trujillo, J. M., Nuffer, W., & Ellis, S. L. (2025). https://pmc.ncbi.nlm.nih.gov/articles/PMC12303005/

Additional information

Size

10mg/vial

What are peptides?

Peptides are short chains of amino acids that act as signalling molecules in the body, playing a role in a wide range of biological processes including tissue repair, immune response, and cellular communication.

How are peptides used in research?

In research settings, peptides are studied for their ability to interact with specific receptors and biological pathways. This makes them valuable tools for scientific and laboratory analysis, helping researchers better understand how the body functions at a cellular level.

What payment methods do you accept?

We currently accept Credit Card, SEPA bank transfer, iDeal, Google Pay, Apple Pay, and Cryptocurrency (Bitcoin, Ethereum, and USDT).

How should I store my peptides?

All peptides are supplied in lyophilised (freeze-dried) form, ensuring stability during shipping and long-term storage. Unreconstituted vials should be kept in a cool, dry place away from direct light, with refrigeration recommended for extended periods. Once reconstituted for research purposes, peptides should be kept refrigerated and handled using sterile laboratory practices to maintain integrity throughout use.

How does shipping and delivery work?

Orders are processed and dispatched within 48 hours of purchase. Delivery typically takes 6-9 business days depending on your location. Tracking information is available directly on our website. Free shipping is applied automatically on all orders over 150 euros.

Do you offer refunds or returns?

Due to the nature of research products, we are unable to accept returns. However if your order arrives damaged or incorrect please contact us within 48 hours.

How can I be sure of product quality?

All our products are lab-tested by Janoshik to ensure high purity and compliance with research-grade quality standards.

Semaglutide

GLP-SM is a synthetic, long-acting analogue of glucagon-like peptide-1 (GLP-1) — a hormone naturally released by the gut after eating. It was originally developed to study blood sugar regulation and has since become one of the most extensively researched peptides in metabolic science (Carvalho et al., 2025).

Mechanism of Action

  • GLP-SM binds to and activates GLP-1 receptors found in the pancreas, brain, gut, and cardiovascular system, triggering insulin release in response to food while simultaneously reducing the release of glucagon — a hormone that raises blood sugar
  • It slows the rate at which the stomach empties, which prolongs feelings of fullness and reduces overall food intake
  • In the brain, GLP-1 receptor activation reduces appetite signals in areas responsible for hunger and reward, contributing to reduced caloric intake (Sikiric et al., 2025)
  • GLP-SM is engineered with a fatty acid side chain that binds to albumin in the bloodstream, extending its half-life to approximately one week and enabling once-weekly dosing (Maharjan & Panda, 2022)

Key Research Findings

  • The STEP clinical trial programme documented a mean body weight reduction of 14.9% with semaglutide 2.4 mg versus 2.4% with placebo in subjects without diabetes over 68 weeks (Carvalho et al., 2025)
  • The SELECT cardiovascular outcomes trial found GLP-SM reduced major adverse cardiovascular events by 20% compared to placebo in subjects with established cardiovascular disease and overweight, but without diabetes (Lincoff et al., 2023)
  • Research also demonstrates benefits in liver fat reduction, kidney function, and heart failure outcomes, pointing to a broad range of metabolic effects beyond blood sugar and weight (Trujillo et al., 2025)

For research use only. Not intended for use in humans or animals.

References

Carvalho, M., Figueiredo, R., & Costa, P. (2025). https://pubmed.ncbi.nlm.nih.gov/40143174/

Lincoff, A. M., Brown-Frandsen, K., Colhoun, H. M., Deanfield, J., Emerson, S. S., Esbjerg, S., & Nissen, S. E. (2023). https://www.nejm.org/doi/full/10.1056/NEJMoa2307563

Maharjan, R., & Panda, S. (2022). https://pmc.ncbi.nlm.nih.gov/articles/PMC8736331/

Sikiric, P., Drmic, D., Zucko, J., & Stupnisek, M. (2025). https://pmc.ncbi.nlm.nih.gov/articles/PMC11674233/

Trujillo, J. M., Nuffer, W., & Ellis, S. L. (2025). https://pmc.ncbi.nlm.nih.gov/articles/PMC12303005/

Related products